Investors

Press Releases

Press Releases

Date Title View
Toggle Summary Liquidia Reports Fourth Quarter and Full-Year 2019 Financial Results and Provides Corporate Update
Submitted New Drug Application (NDA) for LIQ861 in January 2020 Management to Host Webcast and Conference Call Today at 8:00 a.m. ET RESEARCH TRIANGLE PARK, N.C. , March 11, 2020 (GLOBE NEWSWIRE) -- Liquidia Technologies, Inc. (Nasdaq: LQDA) (“Liquidia” or the “Company”), a late-stage clinical
View HTML
Toggle Summary Liquidia to Present at Cowen 40th Annual Health Care Conference
RESEARCH TRIANGLE PARK, N.C. , Feb. 26, 2020 (GLOBE NEWSWIRE) -- Liquidia Technologies, Inc. (Nasdaq:LQDA) (“Liquidia”), a late-stage clinical biopharmaceutical company focused on the development of products using its proprietary PRINT® technology, today announced that Neal Fowler , Chief Executive
View HTML
Toggle Summary Liquidia to Report 2019 Financial Results and Provide Corporate Update on March 11, 2020
RESEARCH TRIANGLE PARK, N.C. , Feb. 26, 2020 (GLOBE NEWSWIRE) -- Liquidia Technologies, Inc. (Nasdaq:LQDA) (“Liquidia”), a late-stage clinical biopharmaceutical company focused on the development of products using its proprietary PRINT® technology, today announced that 2019 financial results will
View HTML
Toggle Summary Liquidia Submits New Drug Application for LIQ861 (treprostinil) inhalation powder to U.S. Food and Drug Administration for the Treatment of Pulmonary Arterial Hypertension (PAH)
RESEARCH TRIANGLE PARK, N.C. , Jan. 27, 2020 (GLOBE NEWSWIRE) -- Liquidia Technologies, Inc. (Nasdaq:LQDA) (“Liquidia”), a late-stage clinical biopharmaceutical company focused on the development of products using its proprietary PRINT® technology, today announced the submission of its New Drug
View HTML
Toggle Summary Liquidia Announces Poster Presentation at the 14th Annual World Congress of the Pulmonary Vascular Research Institute (PVRI)
RESEARCH TRIANGLE PARK, N.C. , Jan. 24, 2020 (GLOBE NEWSWIRE) -- Liquidia Technologies, Inc. (Nasdaq:LQDA) (“Liquidia”), a late-stage clinical biopharmaceutical company focused on the development and commercialization of therapeutics using its proprietary PRINT® technology, today announced that
View HTML
Toggle Summary Liquidia Technologies Announces $22.4 Million Private Placement
RESEARCH TRIANGLE PARK, N.C. , Dec. 24, 2019 (GLOBE NEWSWIRE) -- Liquidia Technologies, Inc. (Nasdaq:LQDA) (“Liquidia”), a late-stage clinical biopharmaceutical company focused on the development and commercialization of therapeutics using its proprietary PRINT ® technology, today announced that it
View HTML
Toggle Summary Liquidia Technologies Reports Third Quarter 2019 Financial Results and Provides Corporate Update
Completed Registrational Studies of LIQ861 to Include in New Drug Application (NDA) Targeting Submission of NDA for LIQ861 in 1Q 2020 Management to Host Webcast and Conference Call Today at 8:00 a.m. ET RESEARCH TRIANGLE PARK, N.C. , Nov. 13, 2019 (GLOBE NEWSWIRE) -- Liquidia Technologies, Inc.
View HTML
Toggle Summary Liquidia to Report Third Quarter 2019 Financial Results and Provide Corporate Update on November 13, 2019
RESEARCH TRIANGLE PARK, N.C. , Nov. 06, 2019 (GLOBE NEWSWIRE) -- Liquidia Technologies, Inc. (Nasdaq: LQDA) (“Liquidia” or the “Company”), a late-stage clinical biopharmaceutical company, today announced that third quarter 2019 financial results will be reported on Wednesday, November 13, 2019 .
View HTML
Toggle Summary Liquidia Technologies Appoints Industry Veteran Katie Rielly-Gauvin to Board of Directors
RESEARCH TRIANGLE PARK, N.C. , Nov. 01, 2019 (GLOBE NEWSWIRE) -- Liquidia Technologies , Inc. (Nasdaq: LQDA) (“Liquidia” or the “Company”), a late-stage clinical biopharmaceutical company, today announced the appointment of Katie Rielly-Gauvin , Vice President of Global Commercial Development at
View HTML
Toggle Summary Liquidia to Present at Cantor 2019 Global Healthcare Conference
RESEARCH TRIANGLE PARK, N.C. , Sept. 25, 2019 (GLOBE NEWSWIRE) -- Liquidia Technologies, Inc. (Nasdaq: LQDA) (“Liquidia” or the “Company”), a late-stage clinical biopharmaceutical company, announced that Neal Fowler , Chief Executive Officer of Liquidia , will present a company overview at the
View HTML